StemCells Inc. (STEM) Short Interest Down 32.8% in November
StemCells Inc. (NASDAQ:STEM) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 1,058,463 shares, a drop of 32.8% from the October 31st total of 1,574,599 shares. Approximately 6.6% of the company’s stock are sold short. Based on an average daily volume of 1,148,056 shares, the days-to-cover ratio is presently 0.9 days.
Separately, S&P Equity Research decreased their price target on StemCells from $1.77 to $0.45 in a research note on Tuesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $13.69.
StemCells (NASDAQ:STEM) opened at 11.52 on Wednesday. The company’s market capitalization is $187.30 million. StemCells has a 52 week low of $0.33 and a 52 week high of $6.96. The stock’s 50 day moving average price is $1.00 and its 200 day moving average price is $1.05.
Several large investors have recently made changes to their positions in STEM. D. E. Shaw & Co. Inc. purchased a new position in StemCells during the third quarter worth $362,000. BlackRock Institutional Trust Company N.A. increased its position in StemCells by 94.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 453,823 shares of the company’s stock worth $617,000 after buying an additional 220,150 shares during the period. Finally, KCG Holdings Inc. increased its position in StemCells by 83.1% in the third quarter. KCG Holdings Inc. now owns 137,489 shares of the company’s stock worth $187,000 after buying an additional 62,394 shares during the period. Institutional investors own 8.76% of the company’s stock.
StemCells, Inc (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.
Receive News & Stock Ratings for StemCells Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc. and related stocks with our FREE daily email newsletter.